TRAP1 and its therapeutic potential

Area of Science:

• Mitochondrial biology
• Molecular medicine
• Oncology

Background:

• Mitochondrial Hsp90 isoform, TRAP1, is implicated in diseases including cancer, ischemic retinopathy, and diabetic kidney disease.
• TRAP1 influences disease pathogenesis by regulating mitochondrial metabolism, apoptosis, oxidative stress, cell signaling, and angiogenesis via client protein interactions.

Purpose of the Study:

• To review TRAP1-selective inhibitors developed to mitigate toxicities of Hsp90 pan-inhibition.
• To explore the potential clinical applications of TRAP1-targeted therapies.

Main Methods:

• Literature review of TRAP1 inhibitors and their mechanisms.
• Analysis of TRAP1's role in disease pathogenesis.
• Examination of preclinical and clinical data on TRAP1-directed therapies.

Main Results:

• TRAP1 plays a critical role in various disease states through its regulation of key cellular processes.
• TRAP1-selective inhibitors have been designed to offer targeted therapeutic benefits.
• These inhibitors aim to reduce the adverse effects associated with non-selective Hsp90 inhibitors.

Conclusions:

• TRAP1 is a promising therapeutic target for diseases such as cancer.
• TRAP1-selective inhibitors represent a viable strategy for disease treatment.
• Further clinical investigation of TRAP1-directed therapies is warranted.